Is it worth buying Sinopharm Biotech (01801.HK) stock? A latest outlook on the stock's prospects.
Innovent Bio (01801.HK) is an investment holding company primarily engaged in the research, development, production, and sales of innovative drugs for the treatment of major diseases such as tumors, cardiovascular and metabolic disorders, autoimmune diseases, and ophthalmic conditions.
For investors, the core of investment decision‑making lies in accurately assessing a company’s growth potential. So, is the current 01801.HK actually worth buying?As a leading financial information service provider, Futubull integrates rating information on each stock from numerous renowned global securities research institutions.It aims to provide users with a comprehensive and timely view of market consensus, helping you accurately identify the optimal entry point.
■According to the latest [Major Brokerage Ratings] data compiled by Futubull (as of April 24, 2026)
Total29A leading analyst is involved in the rating of 01801.HK.Overall Rating：【Strong Buy】
Futubull provides you with professional stock analysis and investment decision support.
In addition to ratings from professional institutions, Futubull takes you, from the perspective of a professional investor, to utilize the “Three-Step Analysis Method” to...Company business, performance status, and technical indicatorsThree core dimensions for a deep dive into stocks, helping you determine whether 01801.HK is worth buying.
■Company Business: What does Innovent Bio do?
Innovent Bio (01801.HK) is an investment holding company established in 2011 and listed on the Main Board of the Hong Kong Stock Exchange in 2018. The company is primarily engaged in the research, development, production, and sales of innovative drugs, with a focus on major disease areas such as oncology, cardiovascular and metabolic diseases, autoimmune diseases, and ophthalmology. Its business covers both the Chinese domestic market and overseas markets.
Oncology drugs
Developing and marketing innovative oncology drugs, including Daboshu, Dayoutong, and Dabohua, is one of the company's core businesses.
Autoimmune disease medications
Developing and marketing drugs for autoimmune diseases, such as the already marketed product Sulixin (adalimumab injection).
Cardiovascular and metabolic, ophthalmic drugs
The company is strategically positioned to develop innovative drugs in the cardiovascular, metabolic, and ophthalmic disease areas, with a product pipeline that encompasses a diverse portfolio of novel drug molecules.
Futubull tooltip:
Facing fragmented information, want to quickly grasp the key priorities of your company’s business?
Simply open the Futubull app, tap the “Company” tab, and scroll down to view Innovent Bio’s “Main Business Composition.” You can clearly and intuitively see Innovent Bio’s primary businesses, flagship products, and market share, helping you quickly analyze the company’s fundamentals.
Futubull breaks down the core business of listed companies for you, helping you understand their fundamentals.
■Performance Dimension: Is Innovent Biologics Profitable?
Futubull's "Earnings Calendar" shows that Innovent Biologics has… --Publish --Performance.
At the same time, Futubull’s “Performance Express” module has compiled the following key performance data for your reference:
| Project | Core data for the quarter | Key changes |
|---|---|---|
| Total Revenue | RMB 13.04 billion | Up 38.4% year over year |
| Product Revenue | 11.9 billion RMB | Up 44.6% year over year |
| IFRS Net Profit | RMB 814 million | Achieved full-year profitability for the first time (compared with a loss of RMB 94.6 million in the same period of 2024). |
| Non-IFRS Net Profit | RMB 1.72 billion | Increased by 419.6% year on year |
| Gross profit margin | 86.5% | An annual increase of 2.5 percentage points (84.0% in 2024) |
| Final dividend | Not recommended for distribution. | - |
Sinopharm Biologics has released its latest financial results, but with such a dense and intricate set of financial reports, do you lack the time to read them in detail—and even find it harder to quickly assess what the data actually means?Major positive newsStillHidden RisksIf you lack the proper interpretation of financial reports, you’ll miss out.Best buying and selling pointsIf there were a reliable tool to help interpret financial reports, it would greatly assist you during earnings season.Seize the initiative and reap profits with ease.。
Futubull's "Performance Express" feature:
Transform complex financial reports into clear, concise insights, enabling you to grasp key data such as revenue and earnings per share—and determine within minutes whether these figures “exceeded expectations” or “fell short of market expectations.”
✓ Positive signal:If the earnings report shows that revenue and net profit significantly outperform market expectations, it generally indicates strong underlying fundamentals for the company. Investors can assess current market conditions and their own risk tolerance to identify potential investment opportunities or make appropriate adjustments to their portfolios.
✓ Risk signal:If key financial indicators show weak performance (or all decline), and both revenue and earnings per share fall short of expectations, this may signal a slowdown in growth. Investors should carefully assess the risks associated with their holdings and, in light of their investment strategies, consider adjusting their portfolio allocations or adopting a wait-and-see approach.
In short, regardless of whether the performance is good or bad, Futubull’s “Performance Express” feature can instantly interpret key data for you, allowing you to confidently enter the market and place orders without having to painstakingly pore over densely packed financial reports.
Open the Futubull App > Individual Stock Page > [Company] Tab—Performance Express—to use this feature for free!
Futubull dissects key financial report data to help you identify buying and selling opportunities before and after earnings releases.
■Technical Indicators: What is the current market sentiment toward Innovent Bio?
The financial data analyzed in “Performance Express” can help you gain a clear understanding of a company’s long‑term growth potential and underlying value; however, to accurately time your entry into a complex market, you still need…Technical IndicatorsProvided real-time signals. Only by anchoring long-term direction with fundamental analysis and locking in short-term opportunities with technical analysis can investment decisions become more stable and more accurate.
Innovent Bio (01801.HK) currently presents 1 "bullish signal" and 1 "bearish signal."
"Optimistic"The closing price broke above the 60-day moving average (MA60) on April 24, potentially signaling a short-term uptrend.
Let it go.On April 24, the 5-day moving average (MA5) crossed below the 20-day moving average (MA20), forming a "death cross," which may signal further price declines.
For those of you who have to return to work and attend meetings on a daily basis, even though you know that the MACD and RSI are crucial, do you simply not have time to monitor the market around the clock? Or perhaps you’re worried about misinterpreting the indicators and can’t tell the difference between...“True Signal”Still"False Breakout"？No need to slog through technical theories—just let “NiuNiu AI” instantly translate market conditions for you!
Futu SupportAI Real‑Time MonitoringIncluding 15 key indicators such as MACD, KDJ, and RSI, these tools directly “translate” complex chart patterns into simple signals—so you no longer need to delve into what “golden crosses and death crosses” or “top and bottom divergences” actually mean, and you can…Easily Grasp Technical Trends。
After understanding Innovent Bio’s technical analysis and forming a preliminary judgment on the overall price trend, to ensure you can react swiftly at critical moments, you may consider using Futubull’s…Price AlertFunction: You can set the following alerts for key areas:
✓ Stock Price Alert: Set up to receive instant notifications when the price breaks above HK$92.0 or falls below HK$81.0.
✓ Indicator AlertSet alerts to trigger when the RSI breaks above 70 or falls below 30.
With Futubull AI, you’ll never have to worry about complex technical indicators again! Download Futubull now and let AI translate technical analysis into clear buy/sell signals—easily distinguishing between “bullish” and “bearish.” Investing has never been so simple and straightforward!
AI-powered real-time interpretation of technical indicators—master buying and selling timing.
■Why do investors choose Futu for trading?
Investing is never a one‑time deal; it's a journey that requires long‑term tracking and dynamic adjustments. Perhaps you don't yet have enough capital to buy Innovent Biologics, or perhaps Innovent Biologics isn't yet worth buying—but you can still use Futubull to track Innovent Biologics over the long term.
Open Futubull,Add Innovent Biologics to your wishlist., you will also reap
Performance Release Reminder：
Before each round of Innovent Biologics' earnings release, Futubull will send you a reminder so you won't miss any earnings opportunity.
Related News Feed：
Real‑time aggregation of major news such as product launches and board changes, enabling you to promptly capture key events that impact Innovent Biologics' stock price.
Institutional Holdings Changes：
Track the flow of "smart money" and gain instant insights into the buying and selling activities of major banks and funds in Sinovac Biotech.
Stock Price Alert：
Set your desired "psychological price point" and never have to monitor the market around the clock—once the stock price of Innovent Biologics pulls back, the system will notify you instantly.
All of the above functions“Free of charge”, download Futubull now and start your professional investment journey!
●Why choose Futu?
Security Assurance
Futu is subject toDual protection from the Hong Kong Investor Compensation Fund (up to HK$500,000) and the U.S. SIPC (up to US$500,000)., all client assets are…Independent Bank Custodyand is equipped with a risk management system developed in-house to ensure data security.
Licensed and compliant
Futu Securities International (Hong Kong) Co., Ltd. isHong Kong’s largest tech-driven brokerage firm (stock code: FUTU)It is also a licensed corporation approved by the Securities and Futures Commission of Hong Kong (CE No.: AZT137).
The company is strictly regulated by the China Securities Regulatory Commission and holds licenses of Class 1, 2, 3, 4, 5, 7, and 9.
Zero-commission trading
Hong Kong stocks, U.S. stocks fractional shares, Crypto0% commission on trades,Help you invest and save more!
Open an account now and enjoy a welcome bonus worth over 1,000 yuan!
Track Sinopharm Biotech's developments for free and trade Hong Kong/US stocks securely and in compliance with regulations.
The content presented above were generated by AI language model with publicly available information and the above material does not represent the position of the company and shall not constitute any investment advice. You may only use the materials on this website for personal reference and non-commercial purposes. Read More
